- Home
- A-Z Publications
- Current Signal Transduction Therapy
- Previous Issues
- Volume 6, Issue 2, 2011
Current Signal Transduction Therapy - Volume 6, Issue 2, 2011
Volume 6, Issue 2, 2011
-
-
Editorial [Hot Topic: Hepatocyte Growth Factor and Its Signalling, New Horizons in Medicine and Therapies (Guest Editors: Wen G. Jiang and Kunio Matsumoto)]
Authors: Wen G. Jiang and Kunio MatsumotoHepatocyte growth factor (HGF, otherwise known as scatter factor, SF) was discovered more than two decades ago. During this period, the HGF receptor, cMET has been identified, the signalling pathways downstream of HGF/cMET have been reported. Two decade on, hepatocyte growth factor, its receptor and cellular signalling have been increasingly recognised as important in a number of physiological processes and pa Read More
-
-
-
Introduction: Hepatocyte Growth Factor and Met Receptor, from Discovery to Therapeutic Implications
More LessThe mechanism for ingenious tissue regeneration in mammals is roughly divided into two distinct systems. One is a system in which undifferentiated, vigorously proliferative stem cells assume the principal role in tissue regeneration. It operates to regenerate and repair tissues comprising differentiated cells that are no longer capable of proliferation, such as the hemopoietic tissue of bone marrow, nerve tissues Read More
-
-
-
The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Authors: Fabiola Cecchi, Daniel C. Rabe and Donald P. BottaroUnder normal conditions, hepatocyte growth factor (HGF)-induced activation of its cell surface receptor, the Met tyrosine kinase (TK), is tightly regulated by paracrine ligand delivery, ligand activation at the target cell surface, and ligand activated receptor internalization and degradation. Despite these controls, HGF/Met signaling contributes to oncogenesis and tumor progression in several cancers and promotes aggressiv Read More
-
-
-
HGF and HGF Agonists, Expression in Wound and Potential Role in the Management of Wound Healing
By Kevin ConwayHepatocyte growth factor (HGF) has been shown to have multiple effects on the wound healing process. Several in vitro and ex vivo models using HGF have been shown to promote wound healing. The expression of HGF and its receptor cMet are different in chronic and acute wounds. HGF treatments in chronic wounds have not lived up to the expectations of the in vitro and ex vivo models. This review looks at the different Read More
-
-
-
Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Authors: Hiroshi Funakoshi and Toshikazu NakamuraHepatocyte growth factor (HGF), which was originally identified and molecularly cloned as a potent mitogen for primary hepatocytes, exhibits multiple biological effects, such as mitogenic, motogenic, morphogenic, and antiapoptotic activities, in the liver and other organs throughout the body by binding to the c-Met/HGF receptor tyrosine kinase (c-Met). In addition to hepatotrophic activities, HGF and c-Met are expressed i Read More
-
-
-
Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications
Authors: Wen G. Jiang and Andrew J. SandersHepatocyte growth factor (HGF) is a known angiogenic factor that has profound effects on vascular endothelial cells. In recent years, it has been reported that the factor also acts as a lymphagiogenic factor that induces lymphangenesis from lymphatic endothelial cells. The current article debates some of the recent evidence showing such an effect and also discusses the clinical studies that link to lymphatic related conditio Read More
-
-
-
HGF and RhoGTPases in Cancer Cell Motility
Authors: Jane Lane, Tracey A. Martin and Wen G. JiangHepatocyte growth factor/scatter factor (HGF/SF) acts as a mitogen, motogen and morphogen as well as an important angiogenic factor. In cancer cells, HGF/SF acts mainly as an inducer of cell migration and invasion with multiple motility signals mediated by the HGF receptor, c-MET. An important component in this signalling chain is the Rho/ROCK pathway, with resultant changes in cytoskeletal arrangement leading to ce Read More
-
-
-
Hepatocyte Growth Factor Signaling in Cancer Metastasis
Authors: Tracey A. Martin, Malcolm D. Mason and Wen G. JiangSince their discovery in the late 1980's, Hepatocyte growth factor (HGF) and it's receptor, c-MET, have become the focus of intense scrutiny as regards their role in cancer and metastasis [1, 2]. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell grow Read More
-
-
-
HGF-Antagonists: Structure, Activities, and Anti-cancer Approach
Hepatocyte growth factor (HGF) and Met receptor participate in the malignant progression of cancer, particularly in invasive growth, metastasis, and drug resistance. Recent studies indicate that the HGF-Met pathway participates in the spreading and maintenance of cancer stem cells, at least in some types of cancers. HGF and Met have become molecular targets of much attention in anticancer therapy. Based on the functiona Read More
-
-
-
Hepatocyte Growth Factor (HGF) for a Cell-Signal-Based Therapy During Acute and Chronic Liver Diseases
Authors: Kiyomasa Oka, Kazuhiro Fukuta and Shinya MizunoIt has been more than 25 years since HGF was discovered as a mitogen of adult rat hepatocytes. HGF is produced in stromal cells, and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor, c-Met. There is now growing evidence to show that stroma-derived HGF is important for organogenesis in embryo and a recovery from diseased conditi Read More
-
-
-
Hepatocyte Growth Factor (HGF), an Endogenous Pulmotrophic Regulator, for the Rescue of Acute and Chronic Lung Diseases
Authors: Shinya Mizuno, Hiroyuki Ohnishi and Toshikazu NakamuraThere is now ample evidence that hepatocyte growth factor (HGF) is essential for organogenesis in embryo and tissue repair for adults in almost all organs. In the lung, HGF elicits mitogenic, morphogenic and anti-apoptotic effects on bronchial and alveolar epithelial cells. HGF also elicits an angiogenic response through enhancing endothelial cell proliferation. Several studies using animal models clearly demonstrated that en Read More
-
-
-
HGF as Angiogenic Factor and Therapeutic Approach
Hepatocyte growth factor (HGF) is a mesenchyme-derived pleiotropic factor which regulates cell growth, cell motility, and morphogenesis of various types of cells, and is thus considered a humoral mediator for morphogenic tissue interactions. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its Read More
-
-
-
HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
Authors: Seiji Yano, Wei Wang, Qi Li, Tadaaki Yamada, Shinji Takeuchi, Kunio Matsumoto, Yasuhiko Nishioka and Saburo SoneThe epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, show dramatic effects against non-small cell lung cancer (NSCLC) with EGFR activating mutations. However, 25%-30% of EGFR mutant lung cancer patients show intrinsic resistance, and the responders almost invariably acquire resistance to EGFR-TKIs within several years. Three mechanisms—second-site point mutation that Read More
-
-
-
Editorial [Hot Topic: Towards Tailored Treatment - New Organ-Specific Drug Strategies Interfering in Signal Transduction (Guest Editors: Jai Prakash and Martin H. de Borst)]
Authors: Jai Prakash and Martin H. de BorstCells regulate normal physiological function by receiving signals from outside as well as providing signals to other cells. These signals are mediated through cytokines, hormones or growth factors which bind to their cognate receptors and trigger receptor-mediated signaling cascades. G-protein coupled receptor kinase, receptor tyrosine kinase, integrin and toll-like receptor pathways cover the most receptor-mediated signaling p Read More
-
-
-
Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Ischemic stroke is a leading cause of morbidity and mortality worldwide which incidence is increasing with society aging. Unfortunately, despite intensive research in treatments to reduce mortality and the severity of the cerebrovascular injury, there are not effective therapies available. Hypoxia-Inducible Factor-1 (HIF-1) triggers the overexpression of genes coding for proteins involved in the adaptative response of the ce Read More
-
-
-
Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Authors: Fariba Poosti, Jan-Luuk Hillebrands, van Goor van Goor and Martin H. de BorstThe increasing prevalence of end-stage renal disease urges novel therapeutic strategies for the treatment of chronic kidney disease. As protein kinases play a pivotal role in renal inflammation and fibrosis, specific protein kinase inhibitors have been demonstrated to be renoprotective in experimental studies. However, since protein kinases are also involved in key physiological mechanisms such as cell differentiation, cell Read More
-
-
-
New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Authors: Fabio Farinati, Nora Cazzagon and Anna GiacominDespite the advancements in diagnosis and therapy for hepatocellular carcinoma (HCC) that currently permit to treat with tailored strategies the disease in early stages, for intermediate and advanced stages the therapeutic options are far from optimal. In recent years, new targets have been searched by exploring the molecular pathways involved in hepatocarcinogenesis, leading to multiple trials on new agents interfering in t Read More
-
-
-
Targeted Delivery of Kinase Inhibitors: A Nanomedicine Approach for Improved Selectivity in Cancer
Authors: Isil Altintas, Raymond Schiffelers and Robbert Jan KokConventional treatment of cancer is accompanied by severe systemic side effects. As an alternative, targeting only deregulated intracellular pathways that cause proliferation, migration and metastasis are emerging in the field of cancer therapy. Kinase inhibitors are one appealing class of drugs that target specific intracellular pathways. However, kinase inhibitors are not specific in terms of tissue or cellular distribution, a Read More
-
-
-
New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Authors: Bradley A. Wisler, James E. Dennis and Charles J. MalemudPro-inflammatory cytokine and anabolic growth factor-mediated activation of the Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT), Stress-activated protein kinase/Mitogen-activated protein kinase (SAPK/MAPK) and Phosphatidylinositide-3-kinase/Phosphatase and TENsin homolog/Akt/mammalian Target Of Rapamycin (PI3K/PTEN/Akt/mTOR) pathways occurs in several autoimmune-mediated inflam Read More
-
Volumes & issues
-
Volume 20 (2025)
-
Volume 19 (2024)
-
Volume 18 (2023)
-
Volume 17 (2022)
-
Volume 16 (2021)
-
Volume 15 (2020)
-
Volume 14 (2019)
-
Volume 13 (2018)
-
Volume 12 (2017)
-
Volume 11 (2016)
-
Volume 10 (2015)
-
Volume 9 (2014)
-
Volume 8 (2013)
-
Volume 7 (2012)
-
Volume 6 (2011)
-
Volume 5 (2010)
-
Volume 4 (2009)
-
Volume 3 (2008)
-
Volume 2 (2007)
-
Volume 1 (2006)
Most Read This Month
Article
content/journals/cst
Journal
10
5
false
en
